Halozyme Therapeutics PE ratio HALO

Share price divided by earnings per share over the last twelve months, since 2020.

Today, Oct 23, 2026: 37.5×
6-year median: 21.3×
Against its 6-year history: 88th; percentile: 0 is its lowest day, 100 its highest
6-year range: 11.6× to 312×
Peer median: 29.4×

Halozyme Therapeutics' PE ratio is 37.5× as of Oct 23, 2026: a share price of $125.63 against $3.35 of earnings per share over the last twelve months.

That is above its 6-year median of 21.3×, higher than on 88% of days in the last 6 years.

Over that time it ranged from 11.6× in Dec 2021 to 312× in Feb 2021.

The median for 10 biotech stocks of a similar size is 29.4×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	37.5×	14.6×	37.5×
2025	14.5×	13.1×	19.3×
2024	15.9×	15.1×	24.7×
2023	19.8×	19.6×	37.2×
2022	38.2×	11.7×	39.9×
2021	14.4×	11.6×	312×
2020	267×	236×	268×

Against its peers

Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.

Company	PE ratio
HALOHalozyme Therapeutics	37.5×
NBIXNeurocrine Biosciences	20.9×
EXELExelixis	20.3×
TECHBIO-TECHNE	63.1×
RGENRepligen	242×
KRYSKrystal Biotech	39.0×
INCYIncyte	14.7×
UTHRUnited Therapeutics	21.0×
ALNYAlnylam Pharmaceuticals	37.8×
ONCBeOne Medicines	67.6×
REGNRegeneron Pharmaceuticals	19.9×
Peer median	29.4×

Where Halozyme Therapeutics ranks

#10of 16Biotech stocks with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Halozyme Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.